About Auronext Pharma Private Limited
Data last updated: 26 July 2025
Auronext Pharma Private Limited was a private limited company based in Hyderabad, Telangana, India, operated as a subsidiary of Aurobindo Pharma Ltd. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It specialised in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 02 July 2009.
Registered with ROC Hyderabad under CIN U74999TG2009PTC109591.
Capital: an authorised share capital of ₹255 Cr and a paid-up capital of ₹124.98 Cr. It was led by directors including Madan Mohan Reddy Mettu and Sapna.
Last AGM: 19 June 2023. Financial statements filed for year ended 31 March 2023. Office: Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032.
As per the financials filed for FY 2023, the company reported a revenue of ₹75.75 Lakh, a growth of 23% compared to the previous year.
The company had a reported workforce of approximately 293 employees prior to being dissolved. It operated as a subsidiary of Aurobindo Pharma Ltd.
The company was associated with 2 brands - Auronext Pharma, Aurobindo Pharma. As per MCA filings, the company had satisfied charges of ₹36.5 Cr on record.
The company has been merged (amalgamated) with another entity and no longer exists separately. Business activities, if any, continue under the successor entity. The last known website on record is aurobindo.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressGalaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032
-
IndustryPharma, Drug Formulation & Development, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Auronext Pharma Private Limited
Auronext Pharma Private Limited has one previous CIN (Corporate Identification Number): U74999DL2009PTC191842. The current CIN is U74999TG2009PTC109591, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U74999TG2009PTC109591 | Current |
| U74999DL2009PTC191842 | Previous |
Associated Brands with Auronext Pharma Private Limited
Auronext Pharma Private Limited operates two associated brands: Auronext Pharma and Aurobindo Pharma. These brands represent Auronext Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com | |
| Offers comprehensive outsourced API production services for the pharmaceutical industry. | auronext.com |
Competitors & Alternatives of Auronext Pharma Private Limited
Brands and companies operating in the same space as Auronext Pharma Private Limited include Laurus Labs, Concord Biotech, Symbiotec and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Business Activity of Auronext Pharma Private Limited
Auronext Pharma Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Auronext Pharma Private Limited
Auronext Pharma Private Limited is audited by G P M & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G P M & Associates | blur-value | blur-value | blur-value |
Board of Directors of Auronext Pharma Private Limited
Auronext Pharma Private Limited is currently managed by 6 directors, with 13 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Madan Mohan Reddy Mettu
Also directs:
Mss Packaging Industries Llp, Aurobindo Pharma Ltd, Engenra Biologics Private Limited and 5 more
|
Director | 31 Aug 2020 | 5 Years 10 Months | As last reported |
| Sapna | Director | 23 May 2019 | 7 Years 1 Months | As last reported |
| Jacob Joseph | Whole-Time Director | 01 Jul 2021 | 5 Years 0 Months | As last reported |
| Venkata Radhakrishna Racharla | Company Secretary | 15 Apr 2019 | 7 Years 2 Months | As last reported |
|
Sarath Chandra Reddy Penaka
Also directs:
Aurobindo Pharma Ltd, Sarath Penaka Enterprises Llp, Naqsh Global Ventures Llp and 5 more
|
Director | 20 Aug 2009 | 16 Years 10 Months | As last reported |
Financials of Auronext Pharma Private Limited FY 2023 filings available
Auronext Pharma Private Limited reported revenue of ₹75.75 Lakh (up 23% YoY) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Auronext Pharma Private Limited
As of FY 2023, Auronext Pharma Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Auronext Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2016 | Yes Bank Limited | ₹35 Cr | Satisfied |
| 02 Feb 2010 | Axis Bank Limited | ₹1.5 Cr | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Auronext Pharma Private Limited
Auronext Pharma Private Limited has a workforce of 293 employees as of Apr 05, 2024.
Employee Count & EPFO Data of Auronext Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Auronext Pharma Private Limited
GSTIN & GST Filing Data of Auronext Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Auronext Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Auronext Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Auronext Pharma Private Limited
MSME Payment Delays by Auronext Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Auronext Pharma Private Limited
Subsidiaries & Group Companies of Auronext Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Auronext Pharma Private Limited with ownership details.
MCA Filings & Documents of Auronext Pharma Private Limited
MCA Filings & Documents of Auronext Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Auronext Pharma Private Limited
Recent News on Auronext Pharma Private Limited
Frequently Asked Questions about Auronext Pharma Private Limited
Auronext Pharma Private Limited has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.
Auronext Pharma Private Limited is a amalgamated private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 02 July 2009 and is registered under CIN U74999TG2009PTC109591. The company was amalgamated as per MCA records and no longer exists as a legal entity.
Auronext Pharma Private Limited was incorporated on 02 July 2009. Registered with ROC Hyderabad.
The current directors of Auronext Pharma Private Limited are:
- Madan Mohan Reddy Mettu
- Ravi Kiran Yellapragada
- Sapna
- Jacob Joseph
- Venkata Radhakrishna Racharla
- Sarath Chandra Reddy Penaka
The CIN (Corporate Identification Number) of Auronext Pharma Private Limited is U74999TG2009PTC109591. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The primary industry of Auronext Pharma Private Limited is pharma. The company specifically operates in drug formulation and development.